PCM
ACET icon

Prelude Capital Management’s Adicet Bio ACET Stock Holding History

Prelude Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Buy
+18,550
New +$146K 0.01% 1026
2025
Q2 		– Sell
-2,140
Closed -$25.9K – 982
2025
Q1 		$25.9K Buy
2,140
+333
+18% +$4.76K ﹤0.01% 1122
2024
Q4 		$27.8K Sell
1,807
-692
-28% -$13.1K ﹤0.01% 1169
2024
Q3 		$57.6K Buy
+2,499
New +$55.9K ﹤0.01% 1204
2024
Q2 		– Sell
-1,738
Closed -$65.4K – 1186
2024
Q1 		$65.4K Buy
+1,738
New +$71.9K ﹤0.01% 1239
2020
Q3 		– Sell
-21
Closed -$5K – 1762
2020
Q2 		$5K Buy
+21
New +$4.13K ﹤0.01% 1706

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Prelude Capital Management's ACET Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Adicet Bio (ACET) in Q2 2026: 18,550 shares worth $160K. The stake represents 0.01% of the portfolio and ranks #1026 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in ACET as recently as Q1 2025.

Prelude Capital Management first reported a position in ACET in Q2 2020 and has held it in 6 quarters since. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Prelude Capital Management held 18,550 shares of Adicet Bio worth $160K as of Q2 2026.
  • Adicet Bio was a new Prelude Capital Management position in Q2 2026.
  • Adicet Bio made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1026 holding.
  • Prelude Capital Management first reported a position in Adicet Bio in Q2 2020 and has held it in 6 quarters since.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.